Century Therapeutics Inc(IPSC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.9 | Insider Own | 32.08% | Shs Outstand | 180.6M | Perf Week | -7.59% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | 14.44% | Insider Trans | -0.02% | Shs Float | 123.0M | Perf Month | -14.62% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.12 | Inst Own | 65.96% | Short Float | 23.69% | Perf Quarter | -27.72% |
| Income | -0.11B | P/S | - | EPS this Y | -274.29% | Inst Trans | 11.31% | Short Ratio | 44.11 | Perf Half Y | -36.24% |
| Sales | 0.00B | P/B | 1.13 | EPS next 5Y | - | ROA | -38.41% | Short Interest | 29.13M | Perf YTD | 46.76% |
| Book/sh | 1.29 | P/C | 2.21 | EPS past 3/5Y | 63.45% 35.31% | ROE | -49.65% | 52W High | -51.97% ($3.04) | Perf Year | 153.16% |
| Cash/sh | 0.66 | P/FCF | - | Sales past 3/5Y | 175.88% - | ROIC | -41.12% | 52W Low | 235.63% ($0.44) | Perf 3Y | 2.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -219.52% | Gross Margin | - | Volatility(W/M) | 7.08% 10.5% | Perf 5Y | -93.5% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.28 | EPS Q/Q | 55.5% | Profit Margin | - | RSI (14) | 44.06 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.28 | Sales Q/Q | - | SMA20 | 0% ($1.46) | Beta | 1.77 | Target Price | $5.12 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/12 | SMA50 | -16.5% ($1.75) | Rel Volume | 2.19 | Prev Close | $1.5 |
| Employees | 78 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | -54.55% - | SMA200 | -30.42% ($2.1) | Avg Volume(3M) | 0.66M | Price | $1.46 |
| IPO | 2021/6/18 | Option/Short | Yes/Yes | Trades | 2314 | Volume | 1,445,895 | Change | -2.67% |
🧬 A clinical-stage biotech company developing allogeneic (off-the-shelf) cell therapies based on induced pluripotent stem cell (iPSC) technology. Headquartered in the United States, the company is building a next-generation immune cell therapy pipeline that uses natural killer (NK) cells and T cells differentiated from iPSCs to target cancer and autoimmune diseases.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
Traded more than usual. That is 219% of its average volume.
IPSC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -274.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #275 of 594 in the industry
Based on market cap of $264M.
CABA#274 Cabaletta Bio Inc $269M PER - IPSC#275 Century Therapeutics Inc $264M PER - 
QTTB#276 Q32 Bio Inc $264M PER 3.0 
ABEO#277 Abeona Therapeutics Inc $261M PER - 
LCTX#278 Lineage Cell Therapeutics Inc $260M PER - 
FAQ
What kind of company is IPSC?
IPSC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IPSC?
The market cap of IPSC is approximately $264M, ranking 3,790 within its sector.
What is the 52-week high and low for IPSC?
IPSC has recorded a 52-week high of $3.04 and a low of $0.44.
